Company Overview and News

14
Blackstone looks to manage US$1 trillion by 2026

2018-09-21 channelnewsasia
Blackstone Group LP , the world's largest manager of alternative investments such as private equity and real estate, said on Friday it could be overseeing US$1 trillion in assets by 2026.
BGX TRI BGLF BX BGB

14
Blackstone looks to manage $1 trillion by 2026

2018-09-21 reuters
NEW YORK (Reuters) - Blackstone Group LP (BX.N), the world’s largest manager of alternative investments such as private equity and real estate, said on Friday it could be overseeing $1 trillion in assets by 2026.
BGX BGLF BX BGB

14
Is A Credit Bubble Underway?

2018-09-21 seekingalpha
A topic which is being discussed with increasing frequency in financial circles is the belief that another credit “bubble” is forming. This fear is perhaps best expressed in a June 8 Washington Post article entitled, “Beware the ‘mother of all credit bubbles’”. A recent increase in high-profile leveraged buyouts has only added fuel to this fear. In today’s comments, I’ll address this concern while providing evidence to dispel the notion that another bubble is upon us.
BGX TRI BGLF BX BGB

15
Akzo Nobel loans break for trading

2018-09-20 reuters
NEW YORK, Sept 20 (LPC) - The US$6.44bn in term loans backing Carlyle Group and Singaporean wealth fund GIC’s acquisition of Akzo Nobel’s chemicals business allocated and broke for trading on Thursday.
BGX STAN DB BNPQY AKZA CG BX BGLF BNPQF BGB BNPZY STAB 580001 STAC SCBFF STAN 2888 MS

14
Blackstone sole bidder to offer all-cash deal for PNB Housing Finance - ET

2018-09-19 reuters
(Reuters) - U.S. private equity firm Blackstone Group LP (BX.N) is the sole bidder to offer an all-cash deal to buy India-based housing finance company PNB Housing Finance Ltd (PNBH.NS), the Economic Times reported on Wednesday.
BGX BGLF BX BGB

14
China's Hillhouse raises US$10.6 bil in Asia's biggest private equity fund

2018-09-19 theedgemarkets
HONG KONG (Sept 19): Hillhouse Capital, an investor in top Chinese technology firms, including Tencent and Baidu, has closed its latest funding round at US$10.6 billion, it said, making it the region's biggest private equity capital raising.
BGX BGLF BX BGB

14
Baring PE Asia in talks to acquire 26% stake in Lakshmi Vilas Bank

2018-09-19 livemint
Mumbai: Baring Private Equity Asia is in talks with Lakshmi Vilas Bank to buy at least a 26% stake in the Chennai-based private lender, said two people close to the development. Lakshmi Vilas Bank is keen to sell as much as 51% if permitted by the Reserve Bank of India (RBI) but bad loans may cloud a potential deal as Baring wants to value the lender at about $400 million, a far cry from Lakshmi Vilas Bank’s expectation of $1 billion, said the two people, who did not want to be named.
BGX LAKSHVILAS 534690 BGLF BX BGB

14
Just How Exuberant is the Junk-Credit Market?

2018-09-18 wolfstreet
This is considered a door-opener Leveraged Buyout (LBO): If it flies and investors buy this $13.5 billion pile of deeply junk-rated debt today, even riskier and bigger LBOs may fly.
BGX TRI BGLF BX BGB

18
Refinitiv loans break for trading

2018-09-18 reuters
NEW YORK, Sept 18 (LPC) - The US$9.25bn in term loans backing private equity firm Blackstone Group’s purchase of a 55% stake in Refinitiv, Thomson Reuters’ Financial and Risk (F&R) division, allocated and broke for trading on Tuesday.
WFCNP BGX DB BGLF MS WFC BX BGB

15
Saudi Wealth Fund to Invest $1 Billion in Tesla's Rival Lucid

2018-09-17 theedgemarkets
(Sept 18): Saudi Arabia’s sovereign wealth fund signed an agreement to invest more than $1 billion in aspiring electric-car maker Lucid Motors Inc., months after building a stake in Elon Musk-led Tesla Inc.
7261 BGX MZDAY OCLCF MZDAF BGLF BX SFTBF 9984 SFTBY ORCL BGB

35
Wall Street is losing clout with China as Trump's trade war mounts

2018-09-17 cnbc
HONG KONG — When President Bill Clinton deliberated whether he should loosen trade barriers against China, Wall Street helped plead Beijing's case.
BGX BGLF GS GLSSP MS GM 8685 JBK AVF GSC TFG BX AIG GSJ BGB GJS

15
Blackstone billionaire: I don't see an economic downturn anywhere on the horizon

2018-09-17 cnbc - 1
There's nothing on the horizon that's indicating the next financial crisis is going to happen anytime soon, according to Tony James, executive vice chairman at the Blackstone Group.
BGX BGFLX BGLF BX BGB

14
RPT-iM Global buys stake in U.S. liquid alternatives firm

2018-09-13 reuters
NEW YORK, Sept 13 (Reuters) - Investment firm iM Global Partner bought a stake in Dynamic Beta investments, a U.S. firm that tries to duplicate large hedge funds’ strategies but for far lower fees.
BGX BGLF BX BGB

14
iM Global buys stake in U.S. liquid alternatives firm

2018-09-13 reuters
NEW YORK (Reuters) - Investment firm iM Global Partner bought a stake in Dynamic Beta investments, a U.S. firm that tries to duplicate large hedge funds’ strategies but for far lower fees.
BGX BGLF BX BGB

24
Saudi Arabia wealth fund prepares to sign US$11bil loan

2018-09-12 thestar.com.my
DUBAI: Saudi Arabia’s sovereign wealth fund will sign an US$11bil loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 09257R101